Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy

Oral Oncology

Volumn 34, Issue 3, 1998, Pages 236-238

  Diz Dios, P ^a,c   Ocampo Hermida, A ^b   Miralles Alvarez, C ^b   Vazquez Garcia E ^a   Martinez Vazquez C ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c NONE   (Spain)

Author keywords

Kaposi's sarcoma; Ritonavir

Indexed keywords

RITONAVIR;

ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CANCER REGRESSION; CASE REPORT; DRUG EFFECT; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL;

EID: 0032078721     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00082-1     Document Type: Note

References (17)

1. [1] Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma. Journal of the American Academy of Dermatology 1993;28:371-375.
2. [2] Orfanos CE, Husak R, Wolfer U, et al. Kaposi's sarcoma: a reevaluation. Recent Results in Cancer Research 1995;139: 275-296.
3. [3] Epstein JB. Management of oral Kaposi's sarcoma and proposal for clinical staging. Oral Diseases 1997;3(Suppl. 1):124-128.
4. [4] Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-1869.
5. [5] Decks S, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. Journal of the American Medical Association 1997;277:145-153.
6. [6] Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-protease inhibitor. AIDS 1997;11:261-262.
7. [7] Conant MA, Opp KM, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS 1997;11:1300-1301.
8. [8] Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991;5:519-535.
9. [9] Real FX, Krown SE. Spontaneous regression of Kaposi's sarcoma in patients with AIDS. New England Journal of Medicine 1985;313:1659.
10. [10] Brooks, JJ. Kaposi's sarcoma: a reversible hyperplasia. Lancet 1986, Dec. 6, 1309-1311.
11. [11] Taylor J, Afrasiabi R, Fahey JL, Korns E, Weaver M, Mitsuyasu R. Prognostically significant classification of immune changes in AIDS with Kaposi's sarcoma. Blood 1986;67:666-671.
12. [12] Lilenbaum RC, Ratner L. Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 1994;8:141-151.
13. [13] Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). British Journal of Dermatology 1989;120:709-713.
14. [14] Lane HC, Falloon J, Walker RE, et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi's sarcoma: a phase II randomized, placebo-controlled trial. Annals of Internal Medicine 1989;111:41-50.
15. [15] Wit R de, Reiss P, Bakker PJM, et al. Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma. AIDS 1989;3:847-850.
16. [16] Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. New England Journal of Medicine 1983;308:1071-1076.
17. [17] Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon alfa with zidovudine: safety, tolerance and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 1990;112:812-821.